Endocrine Response in Women With Invasive Lobular Breast Cancer

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerbreasttumorpriorher2
  Phrases that lowered it: participantparticipantsclinicalendocrinedaily
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 8.3% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 22331 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• ER Reactivation Therapy for Breast Cancer NCT02188745 · started 2016 · scored riskier than 96% of active trials completed
• Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer NCT03747042 · started 2018 · scored riskier than 94% of active trials completed
• Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ NCT01439711 · started 2012 · scored riskier than 60% of active trials completed
• A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause NCT06465368 · started 2024 · scored riskier than 84% of active trials completed
• Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer NCT01368263 · started 2011 · scored riskier than 90% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.